
-
United Therapeutics NasdaqGS:UTHR United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Location: 1000 Spring Street, Silver Spring, MD, 20910, United States | Website: https://www.unither.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
11.33B
Cash
3.321B
Avg Qtr Burn
N/A
Short % of Float
5.04%
Insider Ownership
1.82%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tyvaso (inhaled treprostinil) Details Pulmonary Hypertension (PH) WHO Group 3 | Approved Quarterly sales | |
Remunity™ (treprostinil) Details Pulmonary Hypertension (PH) WHO Group 1 (PAH) | Approved Quarterly sales | |
Tyvaso DPI™ (inhaled treprostinil) Details Pulmonary Hypertension (PH) WHO Group 1 / (PAH)Pulmonary Hypertension (PH) WHO Group 3 | Approved Quarterly sales | |
Tyvaso (inhaled treprostinil) Details Progressive pulmonary fibrosis | Phase 3 Data readout | |
Ralinepag Details Pulmonary hypertension | Phase 3 Data readout | |
Tyvaso (inhaled treprostinil) Details Pulmonary fibrosis, Idiopathic pulmonary fibrosis | Phase 3 Data readout | |
UKidney™ Details End-stage renal disease | Phase 1 Initiation | |
Trevyent® (treprostinil sodium) Details Pulmonary Hypertension (PH) WHO Group 1 (PAH) | Failed Discontinued | |
Tyvaso (inhaled treprostinil) Details Pulmonary hypertension, Chronic obstructive pulmonary disease | Failed Discontinued |